ELI LILLY & Co is 164.1x more valuable than Spyre Therapeutics, Inc. by market capitalization ($1.070 T vs $6.52 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | SYRE | LLY |
|---|---|---|
| Market cap | $6.52 B | $1.070 T |
| US-listed rank | #1201 | #10 |
| Revenue (latest FY) | $0.00 | $65.18B |
| Net income (latest FY) | -$155.20M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 762 | 989 |
ELI LILLY & Co is 164.1x more valuable than Spyre Therapeutics, Inc. by market capitalization ($1.070 T vs $6.52 B).
In their latest fiscal years, Spyre Therapeutics, Inc. reported $0.00 in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Spyre Therapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.